Mephedrone is a synthetic stimulant drug of the amphetamine and cathinone classes. It is chemically similar to the cathinone compounds found in the khat plant of eastern Africa. It comes in the form of tablets or a powder, which users can swallow, snort or inject, producing similar effects to MDMA, amphetamines, and cocaine.
Mephedrone powder is usually sniffed/snorted or swallowed. Swallowing is the most common way of taking the drug. It usually mixed with liquid to drink or wrapped in cigarette paper (known as ‘bombing’). There are reports of people injecting the drug.
Effects of mephedrone
Mephedrone often described as a mix between amphetamines, ecstasy, and cocaine. It can make you feel alert, confident, talkative, and euphoric – and some people will temporarily feel strong affection for those around them.
Mephedrone (4-methylmethcathinone) is a stimulant drug, which means it speeds up the messages traveling between the brain and body.1 Mephedrone is classed among New Psychoactive Substances (NPS), a range of drugs that have been designed to produce effects similar to those of established illicit drugs.
Mephedrone was first synthesised in 1929, but did not become widely known until it was rediscovered in 1999/2000 at which point it was legal to produce and possess in many countries. By 2000, mephedrone was reported to be available for sale on the internet, by 2008 law enforcement agencies had become aware of the compound, and by 2010, it had been reported in most of Europe, becoming particularly prevalent in the United Kingdom. Mephedrone was first made illegal in Israel in 2008, followed by Sweden later that year. In 2010, it was made illegal in many European countries and in December 2010, the EU ruled it illegal. In Australia, New Zealand and the United States, it is considered an analog of other illegal drugs and can be controlled by laws similar to the US Federal Analog Act. In September 2011, the US temporarily classified mephedrone as a Schedule I drug, effective October 2011. This classification was made permanent in July 2012 with the passage of the Synthetic Drug Abuse Prevention Act (SDAPA).